Cognitive Research

PE-22-28 (Spadin)

InvestigationalBrain, mood & sleep
4.9/10

BioHarmony verdict

Neutral

PE-22-28 is a synthetic spadin analogue that blocks the TREK-1 potassium channel, a target with a clean and well-characterized link to fast-acting antidepressant effects in rodents, per Mazella 2010 and Djillani 2017.

Read full report

What is PE-22-28 (Spadin)?

PE-22-28 is a lab-made peptide that blocks the TREK-1 potassium channel, and that single action is the whole pitch. TREK-1 quietly sets how excitable a neuron is, so blocking it raises the firing of serotonin neurons and, in animals, behaves like a fast-acting antidepressant. The target has a genuinely clean backstory: deleting the TREK-1 gene in mice makes them resistant to depression, which is what first put this channel on the map as a depression target, per Mazella 2010. PE-22-28 itself is a 7-amino-acid fragment engineered from spadin, a sortilin-derived peptide, and it was built to hit TREK-1 harder and last longer than its parent, per Djillani 2017.

From the BioHarmony report, reviewed 2026-09-08.

How it is thought to work

Blocks the TREK-1 background potassium channel, raising neuronal excitability and serotonergic firing

Safety watch-outs

  • Palpitations, chest tightness, or blood-pressure swings: stop immediately, since TREK-1 is expressed in heart and vascular tissue and human…
  • Unexplained low blood sugar or shakiness: stop, since TREK-1 blockade acts as an insulin secretagogue in animals.
  • Worsening mood, agitation, or suicidal thinking: stop and seek help, since no human safety or dose-response data exists to guide use.
  • Any sign of contamination, fever, or injection-site infection from grey-market material: stop and seek care.

Full risk profile in the BioHarmony report.

Dosing as published

Animal studyPublished mouse behavioral experiments; not a human dose and not a clinical protocol
PopulationAdult male mice in acute and four-day subchronic experiments
DoseAcute intraperitoneal experiments reported 3.0-4.0 micrograms/kg. The four-day subchronic experiments reported 3.0 micrograms/kg intraperitoneally or 1 mg/kg by gavage.
RouteIntraperitoneal injection or oral gavage, depending on experiment
FrequencyAs specified by each mouse experiment
DurationAcute or four-day subchronic study context
PreparationThe paper's experimental methods are the controlling source; no consumer reconstitution method is established.
Source: Materials and Methods; acute and subchronic administration experiments

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (1)

Attributed viewpoints, separate from primary research.

Trust & sourcing

US approvalInvestigational
CompoundingEligibility not established.
Last checked2026-07-13
Next review2027-01-09

PE-22-28 has published cell and mouse-model research on TREK-1 inhibition and antidepressant-like activity. The reviewed study does not establish human safety or effectiveness.

Primary sources

Free guide

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.